On August 27, Gelonhui reported that Tibet Weixinkang Pharmaceutical (603676.SH) released its 2024 interim report. During the reporting period, the company achieved revenue of 0.633 billion yuan, a decrease of 15.5% year-on-year; net income attributable to the parent company was 0.163 billion yuan, an increase of 21.98% year-on-year; non-GAAP net income was 0.116 billion yuan, a decrease of 11.67% year-on-year; basic earnings per share were 0.38 yuan.
卫信康(603676.SH)：上半年净利润1.63亿元，同比增长21.98%
Tibet Weixinkang Pharmaceutical (603676.SH): The net income in the first half of the year was 0.163 billion yuan, an increase of 21.98% year-on-year.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.